This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Chung, L. Articles by Baxter, R. C. PubMed PubMed Citation Articles by Chung, L. Articles by Baxter, R. C. Related Collections Neuroendocrinology and Pituitary Metabolism

Proteomic Profiling of Growth Hormone-Responsive Proteins in Human Peripheral Blood Leukocytes

Hormones and Cancer Group (L.C., R.C.B.), Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, Sydney NSW 2065, Australia; and Pituitary Research Unit (A.E.N., K.K.Y.H.), Garvan Institute of Medical Research and Department of Endocrinology, St. Vincent’s Hospital, Sydney, NSW 2010 Australia

Address all correspondence and requests for reprints to: Robert C. Baxter, D.Sc., Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St. Leonards, 2065 Australia. E-mail: robaxter{at}med.usyd.edu.au.

Context: GH is a known modulator of the immune system, but the effect of exogenous GH administration on white blood cell proteins has not been investigated. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is a powerful platform for the study of GH effects on immune system proteins.

Objective: Our objective was to explore a novel approach for the detection of GH-responsive proteins in human leukocytes by proteomic analysis using SELDI-TOF MS.

Design: We conducted a randomized double-blind, placebo-controlled GH administration study of 8 wk treatment followed by 6 wk washout. Pre- and posttreatment samples from 30 subjects were used for biomarker discovery.

Setting: The study was performed at a clinical research facility.

Participants: We studied 30 recreationally trained healthy athletes.

Intervention: Subjects received either recombinant human GH (2 mg/d sc; n = 22) or placebo (n = 8) for 8 wk.

Main Outcome Measures: Proteomic profiles were determined using CM10 weak cation-exchange protein chips, and some GH-regulated proteins were purified and identified by mass spectrometry and/or immunoblotting.

Results: SELDI-TOF analysis revealed a number of GH-regulated peptides/proteins in the 3- to 22-kDa range that are either up- or down-regulated by GH. Several of these may be useful as biomarkers of GH action. The calcium-binding, proinflammatory calgranulins S100A8, S100A9, and S100A12 were all significantly down-regulated in response to GH treatment.

Conclusion: This study illustrates the novel use of human leukocyte proteomic profiling by SELDI-TOF MS and reveals the negative regulation of proinflammatory S100 proteins by GH in human white blood cells.